Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 7 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease, Genito Urinary System And Sex Hormones, Hormonal Disorders, Metabolic Disorders, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Constipation, Coronavirus Disease 2019 (COVID-19), Endocrine Gland Disorders, Fatigue, Growth Hormone Deficiency, Idiopathic Short Stature, Ischemia, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Sepsis, Traumatic Brain Injury and Turner Syndrome.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 7 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease, Genito Urinary System And Sex Hormones, Hormonal Disorders, Metabolic Disorders, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Constipation, Coronavirus Disease 2019 (COVID-19), Endocrine Gland Disorders, Fatigue, Growth Hormone Deficiency, Idiopathic Short Stature, Ischemia, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Sepsis, Traumatic Brain Injury and Turner Syndrome.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope
Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
AstraZeneca Plc
Extend Biosciences Inc
Helsinn Group
Lumos Pharma Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Tempest Therapeutics Inc
TheraSource LLC
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EXT-418 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-01 - Drug Profile
Product Description
Mechanism Of Action
HM-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
livoletide - Drug Profile
Product Description
Mechanism Of Action
History of Events
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
Z-505 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
May 25, 2022: Aeterna Zentaris’ licensing partner, Consilient Health announces European launch of Ghryvelin (macimorelin) for diagnosing adult growth hormone deficiency
May 05, 2022: Lumos Pharma announces a clinical collaboration with Massachusetts General Hospital (MGH) to evaluate oral LUM-201 in nonalcoholic fatty liver disease (NAFLD) in a phase 2 investigator-initiated trial
Apr 11, 2022: Lumos Pharma reaches 50% randomization milestone in phase 2 OraGrowtH210 trial evaluating oral LUM-201 in PGHD
Mar 21, 2022: Aeterna Zentaris provides update on ongoing pivotal phase 3 DETECT-Trial for the diagnosis of childhood-onset growth hormone deficiency
Jul 20, 2021: Lumos Pharma announces clinical updates
Jun 28, 2021: Lumos Pharma announces OraGrowtH212 trial of LUM-201 in PGHD is open for enrollment
Jun 03, 2021: Aeterna Zentaris announces final settlement of previously disclosed class-action lawsuit
May 17, 2021: Aeterna Zentaris announces the start of preclinical development of Macimorelin at The University of Queensland as a potential new treatment option for patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease)
May 13, 2021: Aeterna Zentaris commences pivotal phase 3 DETECT-trial for the diagnosis of childhood-onset growth hormone deficiency
Apr 27, 2021: Newly released data on three PGHD patients treated with LUM-201 in prior phase 2 study to be presented in Lumos Pharma Key Opinion Leader Webinar
Apr 21, 2021: Launch of Adlumiz (anamorelin), a Ghrelin Receptor Agonist in Japan
Apr 14, 2021: Lumos Pharma to host key opinion leader event on LUM-201 for the treatment of pediatric growth hormone deficiency
Mar 20, 2021: Data presented at ENDO 2021 differentiate LUM-201 from standard growth hormone secretagogues and further support LUM-201’s potential as a therapeutic for pediatric growth hormone deficiency
Mar 04, 2021: Data supporting use of predictive enrichment markers for Lumos Pharma’s LUM-201 therapy in clinical trials for moderate PGHD published in Journal of the Endocrine Society
Mar 02, 2021: Lumos Pharma to present poster demonstrating greater GH response to LUM-201 than to standard GH secretagogues in PGHD at the Endocrine Society (ENDO) 2021 annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
AstraZeneca Plc
Extend Biosciences Inc
Helsinn Group
Lumos Pharma Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Tempest Therapeutics Inc
TheraSource LLC
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EXT-418 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-01 - Drug Profile
Product Description
Mechanism Of Action
HM-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
livoletide - Drug Profile
Product Description
Mechanism Of Action
History of Events
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
Z-505 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
May 25, 2022: Aeterna Zentaris’ licensing partner, Consilient Health announces European launch of Ghryvelin (macimorelin) for diagnosing adult growth hormone deficiency
May 05, 2022: Lumos Pharma announces a clinical collaboration with Massachusetts General Hospital (MGH) to evaluate oral LUM-201 in nonalcoholic fatty liver disease (NAFLD) in a phase 2 investigator-initiated trial
Apr 11, 2022: Lumos Pharma reaches 50% randomization milestone in phase 2 OraGrowtH210 trial evaluating oral LUM-201 in PGHD
Mar 21, 2022: Aeterna Zentaris provides update on ongoing pivotal phase 3 DETECT-Trial for the diagnosis of childhood-onset growth hormone deficiency
Jul 20, 2021: Lumos Pharma announces clinical updates
Jun 28, 2021: Lumos Pharma announces OraGrowtH212 trial of LUM-201 in PGHD is open for enrollment
Jun 03, 2021: Aeterna Zentaris announces final settlement of previously disclosed class-action lawsuit
May 17, 2021: Aeterna Zentaris announces the start of preclinical development of Macimorelin at The University of Queensland as a potential new treatment option for patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease)
May 13, 2021: Aeterna Zentaris commences pivotal phase 3 DETECT-trial for the diagnosis of childhood-onset growth hormone deficiency
Apr 27, 2021: Newly released data on three PGHD patients treated with LUM-201 in prior phase 2 study to be presented in Lumos Pharma Key Opinion Leader Webinar
Apr 21, 2021: Launch of Adlumiz (anamorelin), a Ghrelin Receptor Agonist in Japan
Apr 14, 2021: Lumos Pharma to host key opinion leader event on LUM-201 for the treatment of pediatric growth hormone deficiency
Mar 20, 2021: Data presented at ENDO 2021 differentiate LUM-201 from standard growth hormone secretagogues and further support LUM-201’s potential as a therapeutic for pediatric growth hormone deficiency
Mar 04, 2021: Data supporting use of predictive enrichment markers for Lumos Pharma’s LUM-201 therapy in clinical trials for moderate PGHD published in Journal of the Endocrine Society
Mar 02, 2021: Lumos Pharma to present poster demonstrating greater GH response to LUM-201 than to standard GH secretagogues in PGHD at the Endocrine Society (ENDO) 2021 annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aeterna Zentaris Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Extend Biosciences Inc, 2022
Pipeline by Helsinn Group, 2022
Pipeline by Lumos Pharma Inc, 2022
Pipeline by Oxeia Biopharmaceuticals Inc, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by RaQualia Pharma Inc, 2022
Pipeline by Tempest Therapeutics Inc, 2022
Pipeline by TheraSource LLC, 2022
Pipeline by Zeria Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aeterna Zentaris Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Extend Biosciences Inc, 2022
Pipeline by Helsinn Group, 2022
Pipeline by Lumos Pharma Inc, 2022
Pipeline by Oxeia Biopharmaceuticals Inc, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by RaQualia Pharma Inc, 2022
Pipeline by Tempest Therapeutics Inc, 2022
Pipeline by TheraSource LLC, 2022
Pipeline by Zeria Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
